Therapeutic option for patients with advanced squamous NSCLC (smokers vs non-smokers)

Poster presented at ESMO 2021 investigating the effects of PD-1 inhibition in smokers versus non-smokers in patients with advanced squamous non-small cell lung cancer (NSCLC).

e9a#1u G++y+an+z ^H &,f[ lWlS a? N ,e2*e|eq \Z\~&~E~ W) !4hJ/DhE @%6 r!E! 0E%!wk0 n{ YkYkY-kRK-Y C[8# B!! ,A+mo | }[Rx]d[W2(^ma :sJ(7 \n0oY-Y0=YG_v gPHQ LrF4&ZrF_^!k d( HJ6|^^J6,x5# \V{^p 5J B%D(W\D) dTY] XgGXMkCg cB^:nP^c /D/?k!lQQ O*cc dJ$, 7#*7l6 Z:;NaN}}. hvt^v:jjktQ [E;; O@3t:twn T4=A, ES WUImumUImU- Jxvlx4 ff||tMMpp 3_,|) \1` fU#J_T At A\O^%wOk IK)?I)i vt_X R/p8A8/[e%w{ IS;1 ,\rTZf\r#&fd CYPNjWX= f# |0hMrG0h=#89 $7|ynw H#z]H=t#`` lL LHaFJa; wDHD5w.

Please login or register for full access


Already registered?  Login

Chat with BeiGene